18 and older, any sex, with Adenocarcinoma of the Gastroesophageal Junction or Diffuse Adenocarcinoma of the Stomach. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of HER2 Negative, Positive, or Equivocal Participants With Either Negative or Positive Tumor ReadingsPrimary· Up to 1 year
The reading of the 64CuDOTA-trastuzumab-PET imaging of the study subjects were performed by two radiologists, one who read the first scan and the second nuclear radiologist read the remaining seven scans. To eliminate potential bias, the second nuclear radiologist was blinded to the HER2 status of the tumors as well as the location of the tumor until radiolabeled uptake was measured. XD (version 3.6; Miranda Medical) was used for image analysis.Tumor visualized as "hot" relative to adjacent tissue reported per radiologist as negative, positive, equivocal or unknown.
HER2 Negative, Tumor Visual Negative
Group
Value
95% CI
Diagnostic (Copper Cu 64-DOTA-trastuzumab PET Scan)
5
HER 2 Positive, Tumor Visual Negative
Group
Value
95% CI
Diagnostic (Copper Cu 64-DOTA-trastuzumab PET Scan)
1
HER 2 Equivocal, Tumor Visual Negative
Group
Value
95% CI
Diagnostic (Copper Cu 64-DOTA-trastuzumab PET Scan)
2
HER2 Negative, Tumor Visual Positive
Group
Value
95% CI
Diagnostic (Copper Cu 64-DOTA-trastuzumab PET Scan)
0
HER 2 Positive, Tumor Visual Positive
Group
Value
95% CI
Diagnostic (Copper Cu 64-DOTA-trastuzumab PET Scan)
0
HER 2 Equivocal, Tumor Visual Positive
Group
Value
95% CI
Diagnostic (Copper Cu 64-DOTA-trastuzumab PET Scan)
0
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events were collected over a period of 2 years and 4 months..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Diagnostic (Copper Cu 64-DOTA-trastuzumab PET Scan)
This pilot clinical trial studies copper Cu 64 (64Cu) tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET)/computed tomography (CT) in studying patients with gastric, or stomach cancer. Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab PET/CT, may help doctors study the characteristics of tumors and choose the best treatment.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT02226276 — Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Me
· NA
· active not recruiting
NCT01093612 — Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
· NA
· active not recruiting
Other recruiting trials for Adenocarcinoma of the Gastroesophageal Junction
Currently open trials in the same condition.
NCT04028167 — Induction FLOT With CROSS CRT for Esophageal Cancer
· Phase 2
· active not recruiting
Other City of Hope Medical Center trials
Trials by the same sponsor.
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant
· Phase 2
· not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
· Phase 2
· not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment
· Phase 1
· not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o
· NA
· withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 28 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01939275.